Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Total Current Liabilities
All obligations due within one year.
Lucid Diagnostics Inc.NASDAQ: LUCD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 19.6% from a year ago
Total current liabilities stood at $29.39M at the end of Q1 FY2026, down 19.6% from a year earlier and up 2.8% from the prior quarter. Over 3 fiscal years it compounded at +50.3% a year.
Context
- Total current liabilities amounted to 86.2% of total assets at the end of Q1 FY2026, down 25.3 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -19.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.58M USD
- Year-over-year change
- +21.5%
- 4-year CAGR
- +60.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.58M | +21.5% |
| FY2024 | 2024-12-31 | 23.52M | -19.9% |
| FY2023 | 2023-12-31 | 29.38M | +248.7% |
| FY2022 | 2022-12-31 | 8.43M | +97.8% |
| FY2021 | 2021-12-31 | 4.26M | — |
Total Current Liabilities vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's Mar 2026 total current liabilities of $29.39M is the 4th highest of the 10 companies compared; the peer median is $13.69M.
- Its year-over-year change of -19.6% is the 7th highest of 10, against a peer median of -0.7%.
- Total current liabilities amounts to 86.2% of total assets for LUCD, versus a peer median of 15.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $501.75M | +82.0% | +120.9% | 170.9% | |
| Mar 2026 | $66.67M | +190.4% | +80.3% | 129.3% | |
| Mar 2026 | $48.14M | +18.3% | -12.8% | 55.5% | |
| Mar 2026 | $29.39M | -19.6% | +50.3% | 86.2% | |
| Mar 2026 | $19.12M | +27.5% | -1.0% | 30.7% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $13.69M | -5.1% | +52.3% | 4.6% |
| Mar 2026 | $10.24M | -22.4% | +7.6% | 3.8% | |
| Mar 2026 | $9.45M | -0.7% | -0.4% | 15.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $9.34M | -61.5% | +41.4% | 14.0% |
| Mar 2026 | $2.22M | -74.3% | +32.8% | 1.2% | |
| Peer median (excluding LUCD) | $13.69M | -0.7% | +32.8% | 15.0% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 53.66M | 22.47M | 18.9M | 22.36M | 34.71M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 200K | 17K | 45K | 405K | 643K |
| Inventory | 493K | 111K | 278K | 341K | 353K |
| Other Current Assets | 0 | 0 | 1.98M | 0 | 0 |
| Total Current Assets | 57.3M | 24.36M | 22.07M | 25.15M | 37.47M |
| Property, Plant & Equipment (Net) | 971K | 3.6M | 2.64M | 3.7M | 2.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 3.45M | 1.42M | 736K | 315K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 725K | 1.11M | 1.13M | 1.13M | 47K |
| Total Non-current Assets | 1.7M | 8.15M | 5.2M | 5.57M | 2.98M |
| Total Assets | 59M | 32.51M | 27.27M | 30.72M | 40.45M |
| Account Payables | 1.49M | 1.06M | 1.15M | 1.24M | 970K |
| Short-term Debt | 0 | 0 | 13.95M | 18.6M | 24M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 936K | 0 | 0 |
| Other Current Liabilities | 557K | 5.53M | 791K | 1.35M | 2.04M |
| Total Current Liabilities | 4.26M | 8.43M | 29.38M | 23.52M | 28.58M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 1.04M | 199K | 1.8M | 927K |
| Total Liabilities | 4.26M | 9.46M | 29.58M | 25.32M | 29.51M |
| Common Stock | 35K | 41K | 42K | 63K | 131K |
| Retained Earnings | (41.9M) | (98.08M) | (150.74M) | (203.77M) | (274.34M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 54.74M | 23.05M | (2.31M) | 5.39M | 10.94M |
| Total Debt | 0 | 2M | 15.26M | 21.25M | 25.82M |
| Net Debt | (53.66M) | (20.48M) | (3.64M) | (1.1M) | (8.89M) |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.